TARS — Tarsus Pharmaceuticals Balance Sheet
0.000.00%
- $3.45bn
- $3.12bn
- $182.95m
- 61
- 17
- 81
- 53
Annual balance sheet for Tarsus Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 168 | 172 | 217 | 227 | 291 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.02 | 0.092 | 3.58 | 17.7 | 48.1 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 171 | 176 | 225 | 256 | 357 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.24 | 1.83 | 1.53 | 3.35 | 2.87 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 172 | 179 | 228 | 265 | 377 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 5.39 | 11.5 | 15.4 | 36.9 | 80.6 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 5.99 | 12.2 | 35 | 68.5 | 152 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 166 | 167 | 193 | 197 | 225 |
| Total Liabilities & Shareholders' Equity | 172 | 179 | 228 | 265 | 377 |
| Total Common Shares Outstanding |